lifestyle.ebusinessplanet.com

Author: Tris Pharma, Inc.

Tris Pharma Appoints Jim Potenziano, Ph.D. as Chief Science and Development Officer

May 5, 2026
Tris Pharma to Showcase Encore Phase 3 Data Supporting Continued Progress in Acute Pain Treatment at ASRA 2026 Meeting in Phoenix

April 8, 2026
Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting

March 12, 2026